Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 4/20 | 0.82 |
| ▸ | THRB | P10828 | 1/20 | 0.82 |
| ▸ | MAPT | P10636 | 1/20 | 0.68 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.61 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.61 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.61 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26689829 | 1.00 | TP53 (0.82) | TP53THRBMAPTCYP1A2CYP3A4 | |
| SCHEMBL24045329 | 0.90 | TP53 (0.81) | TP53THRBMAPT | |
| SCHEMBL24045262 | 0.89 | TP53 (1.00) | TP53THRBMAPTCYP1A2CYP3A4 | |
| SCHEMBL24045322 | 0.88 | MAPT (0.75) | TP53THRBMAPT | |
| SCHEMBL24045260 | 0.88 | MAPT (0.75) | TP53THRBMAPT | |
| SCHEMBL24943939 | 0.88 | TP53 (0.81) | TP53THRBMAPTCYP1A2CYP3A4 | |
| SCHEMBL24045328 | 0.82 | TP53 (0.71) | TP53MAPT | |
| SCHEMBL24045352 | 0.82 | MAPT (0.83) | TP53THRBMAPT | |
| SCHEMBL24045330 | 0.81 | MAPT (1.00) | TP53THRBMAPT | |
| SCHEMBL24045258 | 0.79 | MAPT (0.89) | TP53THRBMAPTCYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2023-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230339878-A1 | SLC26A3 INHIBITORS AND USE THEREOF | SLC26A3, SLC10A2, SLC10A6 | TP53 3893/4885THRB 881/4885MAPT 2923/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.